Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Rosy outlook, newly issued patents boost VistaGen Therapeutics’ antidepressant AV-101, says Oppenheimer

Wednesday, June 13, 2018 13:33
% of readers think this story is Fact. Add your two cents.

Analysts at Oppenheimer said Friday that a “rosy outlook” and newly issued patents elevated VistaGen Therapeutics Inc.’s (NASDAQ:VTGN) new generation antidepressant AV-101.

The analysts said that the US Patent and Trademark Office has issued two key patents for VistaGen’s lead asset AV-101.

“Management estimates that these patents would not expire until at least 2034 and represent a fundamental milestone,” wrote Oppenheimer analysts Jay Olson and Silvan Tuerkcan in a note to clients.

“We believe VistaGen’s unique antidepressant (AV-101) may offer ketamine-like efficacy without the side effects or inconvenience, and recently initiated coverage with a US$6 price target,” they added.

READ: VistaGen Therapeutics rockets after Oppenheimer initiates coverage with Outperform rating, US$6 price target

The analysts said VistaGen currently has a pair of Phase 2 trials running to demonstrate the “efficacy and safety of AV-101 in patients with depression and an inadequate response to at least one prior treatment.”

Data from the first, smaller trial, with 25 participants, is expected to come in by the end of 2018. The second, larger trial with 180 subjects isn’t expected to throw up results until mid-2019.

Investment thesis

The Oppenheimer note indicated that if the Phase 2 trials are successful, VistaGen could begin pivotal trials by early-2020, with potential NDA filing in 2022. The antidepressant would then be expected to launch in the United States in 2023.

“We estimate 4 million major depressive disorder (MDD) patients in the US are candidates for AV-101,” wrote the analysts. “We forecast a peak 5% market share and $7,000 annual net price, implying peak sales of $1.5bn with 25% probability of success and $373 million risk-adjusted sales in 2030.”

The analysts viewed VistaGen as “underappreciated and undervalued,” with a novel, “potentially best-in-class, rapid acting” oral antidepressant.

“We assume that AV-101 has a product life cycle lasting until at least 2030,” the analysts said in their base case assumption.

Shares of the biotech were trading 3.3% higher at US$1.46 on Wednesday.

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/198819/rosy-outlook-newly-issued-patents-boost-vistagen-therapeutics-antidepressant-av-101-says-oppenheimer-198819.html

We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

Loading...

Top Global

Top Alternative

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.